Axsome Therapeutics, Inc. AXSM
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-5.64
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $638.5M | -$183.2M | — | -$93.9M | $88.3M |
| 2024 | $385.7M | -$287.2M | — | -$128.7M | $57.0M |
| 2023 | $270.6M | -$239.2M | — | -$145.7M | $191.0M |
| 2022 | $50.0M | -$187.1M | — | -$117.2M | $109.6M |
| 2021 | — | -$130.4M | — | -$108.5M | $15.6M |
| 2020 | — | -$102.9M | — | -$78.5M | $113.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| JEFFS ROGER | director | 2026-06-11 | Sell | 286 | $249.12 |
| JEFFS ROGER | director | 2026-06-10 | Sell | 286 | $246.18 |
| Mahony Susan | director | 2026-06-10 | Sell | 300 | $246.18 |
| Coleman Mark | director | 2026-06-10 | Sell | 643 | $249.00 |
| TABUTEAU HERRIOT | Chief Executive Officer | 2026-06-09 | Option exercise | 49,670 | $4.95 |
| TABUTEAU HERRIOT | Chief Executive Officer | 2026-06-09 | Sell | 49,670 | $241.01 |
| Pizzie Nick | Chief Financial Officer | 2026-06-09 | Option exercise | 33,000 | $3.50 |
| Mahony Susan | director | 2026-06-09 | Sell | 300 | $237.21 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.64 (distress)
- Working capital / assets 0.305
- Retained earnings / assets -1.893
- EBIT / assets -0.242
- Equity / liabilities 0.147
Source: SEC EDGAR filings · CIK 0001579428 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.